Letairis and Nephropathy - a phase IV clinical study of FDA data

Summary:

Nephropathy is reported as a side effect among people who take Letairis (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Adcirca, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Nephropathy when taking Letairis. It is created by eHealthMe based on reports of 93,991 people who have side effects when taking Letairis from the FDA, and is updated regularly.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

What is Nephropathy?

Nephropathy (damage to or disease of a kidney) is found to be associated with 894 drugs and 736 conditions by eHealthMe. Check the latest studies of Nephropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

93,991 people reported to have side effects when taking Letairis.
Among them, 19 people (0.02%) have Nephropathy.

Among these 19 people:

How long have people been on Letairis when they have Nephropathy? *

What is the gender of people who have Nephropathy when taking Letairis? *

female: 68.42 %
male: 31.58 %

What is the age of people who have Nephropathy when taking Letairis? *

What are other drugs people take besides Letairis? *

What are other side effects people have besides Nephropathy? *

Nausea (feeling of having an urge to vomit): 4 people, 21.05%
Hospitalisation: 4 people, 21.05%
Staphylococcal Infection (an infection with staphylococcus bacteria): 3 people, 15.79%
Fever: 3 people, 15.79%
Nausea And Vomiting: 3 people, 15.79%
Chills (felling of cold): 3 people, 15.79%
Dyspnea (difficult or laboured breathing): 2 people, 10.53%
Fatigue (feeling of tiredness): 2 people, 10.53%
Retching (strong involuntary effort to vomit): 2 people, 10.53%
Diarrhea: 2 people, 10.53%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.26%
Portopulmonary Hypertension (coexistence of portal and pulmonary hypertension): 1 person, 5.26%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 5.26%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Letairis and have Nephropathy?

- Check whether Nephropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letairis:

Letairis (94,041 reports)

Nephropathy treatments and more:

Nephropathy (16,529 reports)

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephropathy:

Nephropathy (894 drugs)

Browse all the conditions that are associated with Nephropathy:

Nephropathy (736 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Letairis) and Letairis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.